Literature DB >> 9106343

Equine herpesvirus 1 myeloencephalopathy.

W D Wilson1.   

Abstract

Myeloencephalopathy is an uncommon manifestation of equine herpesvirus 1 (EHV-1), but it can cause devastating losses during outbreaks on individual farms. Clinical signs of neurologic disease reflect a diffuse multifocal hemorrhagic myeloencephalopathy secondary to vasculitis and thrombosis. Sudden onset and early stabilization of signs, including ataxia, paresis, and urinary incontinence; involvement of multiple horses on the premises; and recent history of fever, abortion, or viral respiratory disease in the affected horse or herdmates are typical features, although there is considerable variation between outbreaks in epidemiologic and clinical findings. Prevention is difficult because many asymptomatic horses are infected latently with EHV-1 myeloencephalopathy and because vaccines do not confer protection against neurologic manifestations of infection. This article reviews the pathogenesis, pathology, clinical manifestations, diagnosis, and treatment of EHV-1 myeloencephalopathy and discusses prevention and control of equine herpesviral infections in the context of their epidemiology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106343     DOI: 10.1016/s0749-0739(17)30255-9

Source DB:  PubMed          Journal:  Vet Clin North Am Equine Pract        ISSN: 0749-0739            Impact factor:   1.792


  14 in total

1.  Equine Herpesvirus Type 1 Enhances Viral Replication in CD172a+ Monocytic Cells upon Adhesion to Endothelial Cells.

Authors:  Kathlyn Laval; Herman W Favoreel; Katrien C K Poelaert; Jolien Van Cleemput; Hans J Nauwynck
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

2.  Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks.

Authors:  J Nugent; I Birch-Machin; K C Smith; J A Mumford; Z Swann; J R Newton; R J Bowden; G P Allen; N Davis-Poynter
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  Equine herpesvirus myeloencephalopathy in a 14-year-old quarter horse stallion.

Authors:  T F Olsen
Journal:  Can Vet J       Date:  2001-03       Impact factor: 1.008

4.  Glycoproteins D of equine herpesvirus type 1 (EHV-1) and EHV-4 determine cellular tropism independently of integrins.

Authors:  Walid Azab; Nikolaus Osterrieder
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

5.  Equine herpesvirus 1 entry via endocytosis is facilitated by alphaV integrins and an RSD motif in glycoprotein D.

Authors:  Gerlinde R Van de Walle; Sarah T Peters; Brian C VanderVen; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

6.  Equine herpesvirus-1, non-neurogenic pathotype, in a 9-year-old American Saddlebred with neurological signs.

Authors:  Tammy M-J Heerkens
Journal:  Can Vet J       Date:  2009-03       Impact factor: 1.008

7.  Meningoencephalitis in mice infected with an equine herpesvirus 1 strain KyA recombinant expressing glycoprotein I and glycoprotein E.

Authors:  Arthur R Frampton; Patrick M Smith; Yunfei Zhang; Warren D Grafton; Tomio Matsumura; Nikolaus Osterrieder; Dennis J O'Callaghan
Journal:  Virus Genes       Date:  2004-08       Impact factor: 2.332

8.  Comparative Genomic Sequencing and Pathogenic Properties of Equine Herpesvirus 1 KyA and RacL11.

Authors:  Akhalesh K Shakya; Dennis J O'Callaghan; Seong K Kim
Journal:  Front Vet Sci       Date:  2017-12-11

9.  Pollens destroy respiratory epithelial cell anchors and drive alphaherpesvirus infection.

Authors:  Jolien Van Cleemput; Katrien C K Poelaert; Kathlyn Laval; Francis Impens; Wim Van den Broeck; Kris Gevaert; Hans J Nauwynck
Journal:  Sci Rep       Date:  2019-03-18       Impact factor: 4.379

10.  A point mutation in a herpesvirus polymerase determines neuropathogenicity.

Authors:  Laura B Goodman; Arianna Loregian; Gillian A Perkins; Josie Nugent; Elizabeth L Buckles; Beatrice Mercorelli; Julia H Kydd; Giorgio Palù; Ken C Smith; Nikolaus Osterrieder; Nicholas Davis-Poynter
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.